Compare Charles Schwab Corporation Common Stock (SCHW) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs 10X Genomics Inc — how do they compare? Charles Schwab Corporation Common Stock trades at $96.95 (market cap $167.52B), while 10X Genomics Inc trades at $78.76 (market cap $10.07B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 16.6× 10X Genomics Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles Schwab Corporation Common Stock for 85 Days and 10X Genomics Inc for 92 Days on average.
| SCHW | TXG | |
|---|---|---|
Market Cap | $167.52B | $10.07B |
Volume | 6,554,126 | 5,657,286 |
Sector | Financials | Health |
52-Week High | $113.65 | $97.74 |
52-Week Low | $85.35 | $11.48 |
Typical Hold Time | 85 Days | 92 Days |
Enterprise Value | $153.97B | $9.59B |
Dividend Yield | 1.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $95.58, down 1.26% today, with a bearish technical signal. The stock shows strong fundamentals, with Q2 2026 EPS beating expectations at $1.62 and revenue growth to $23.92B in 2025. Analyst consensus is bullish, with a $119.92 price target, supported by recent news of a secondary listing on the Texas Stock Exchange and AI integration for advisors.
Outlook remains positive due to earnings momentum and market share gains, but risks include competitive pressures and interest rate sensitivity. The stock offers upside from current levels if execution continues, though technical weakness may persist near-term.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
